

# Mark A Pallansch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2881326/publications.pdf>

Version: 2024-02-01

32  
papers

3,081  
citations

257450

24  
h-index

414414

32  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1596  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of disruptions caused by the COVID-19 pandemic on global polio eradication. <i>Vaccine</i> , 2023, 41, A12-A18.	3.8	24
2	Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response. <i>Vaccine</i> , 2023, 41, A136-A141.	3.8	12
3	Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal. <i>Vaccine</i> , 2023, 41, A70-A78.	3.8	3
4	Global Transmission of Live Polioviruses: Updated Dynamic Modeling of the Polio Endgame. <i>Risk Analysis</i> , 2021, 41, 248-265.	2.7	38
5	Updated Characterization of Outbreak Response Strategies for 2019â€“2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain. <i>Risk Analysis</i> , 2021, 41, 329-348.	2.7	36
6	Updated Characterization of Postâ€“OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart. <i>Risk Analysis</i> , 2021, 41, 320-328.	2.7	29
7	Updated Characterization of Poliovirus Transmission in Pakistan and Afghanistan and the Impacts of Different Outbreak Response Vaccine Options. <i>Journal of Infectious Diseases</i> , 2021, 224, 1529-1538.	4.0	11
8	Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial. <i>Vaccine</i> , 2021, 39, 5814-5821.	3.8	5
9	Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. <i>Science</i> , 2020, 368, 401-405.	12.6	105
10	Progress Toward Poliovirus Containment Implementation â€” Worldwide, 2019â€“2020. <i>Morbidity and Mortality Weekly Report</i> , 2020, 69, 1330-1333.	15.1	9
11	Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2624-2634.	13.7	30
12	Maintenance and Intensification of Bivalent Oral Poliovirus Vaccine Use Prior to its Coordinated Global Cessation. <i>Journal of Vaccines &amp; Vaccination</i> , 2016, 7, .	0.3	25
13	Standardized Methods for Detection of Poliovirus Antibodies. <i>Methods in Molecular Biology</i> , 2016, 1387, 145-176.	0.9	97
14	Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame. <i>BMC Infectious Diseases</i> , 2016, 16, 137.	2.9	49
15	Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. <i>Vaccine</i> , 2015, 33, 6816-6822.	3.8	89
16	An economic analysis of poliovirus risk management policy options for 2013â€“2052. <i>BMC Infectious Diseases</i> , 2015, 15, 389.	2.9	63
17	Modeling Options to Manage Type 1 Wild Poliovirus Imported Into Israel in 2013. <i>Journal of Infectious Diseases</i> , 2015, 211, 1800-1812.	4.0	63
18	Estimating the Likely Coverage of Inactivated Poliovirus Vaccine in Routine Immunization: Evidence From Demographic and Health Surveys. <i>Journal of Infectious Diseases</i> , 2014, 210, S465-S474.	4.0	13

#	ARTICLE	IF	CITATIONS
19	Expert Review on Poliovirus Immunity and Transmission. Risk Analysis, 2013, 33, 544-605.	2.7	97
20	Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses. Risk Analysis, 2013, 33, 647-663.	2.7	63
21	Review and Assessment of Poliovirus Immunity and Transmission: Synthesis of Knowledge Gaps and Identification of Research Needs. Risk Analysis, 2013, 33, 606-646.	2.7	71
22	Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine-Related Polioviruses. Risk Analysis, 2013, 33, 703-749.	2.7	89
23	Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine-Derived Polioviruses (cVDPVs). Risk Analysis, 2013, 33, 680-702.	2.7	97
24	Multiple Independent Emergences of Type 2 Vaccine-Derived Polioviruses during a Large Outbreak in Northern Nigeria. Journal of Virology, 2013, 87, 4907-4922.	3.4	142
25	Fractional Doses of Inactivated Poliovirus Vaccine in Oman. New England Journal of Medicine, 2010, 362, 2351-2359.	27.0	154
26	Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine, 2010, 28, 4312-4327.	3.8	52
27	Risks of Paralytic Disease Due to Wild or Vaccine-Derived Poliovirus After Eradication. Risk Analysis, 2006, 26, 1471-1505.	2.7	154
28	VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION. Annual Review of Microbiology, 2005, 59, 587-635.	7.3	610
29	Circulating vaccine-derived polioviruses: current state of knowledge. Bulletin of the World Health Organization, 2004, 82, 16-23.	3.3	135
30	Polio eradication: the OPV paradox. Reviews in Medical Virology, 2003, 13, 277-291.	8.3	114
31	Serial Recombination during Circulation of Type 1 Wild-Vaccine Recombinant Polioviruses in China. Journal of Virology, 2003, 77, 10994-11005.	3.4	79
32	Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus. Science, 2002, 296, 356-359.	12.6	523